BR0010099A - Métodos para modular a agregação de amilóides em um indivìduo, para o tratamento de um estado doentio associado com amiloidose, composição para modular amiloidose, e, métodos para inibir os depósitos de amilóide associados com iapp em um indivìduo, para inibir fibrilogenese iapp em um indivìduo, para reduzir os agregados de amilóides associados com iapp em um indivìduo, para modular dano associado com amilóides em células, e para modular amiloidose in vivo ou ex vivo - Google Patents

Métodos para modular a agregação de amilóides em um indivìduo, para o tratamento de um estado doentio associado com amiloidose, composição para modular amiloidose, e, métodos para inibir os depósitos de amilóide associados com iapp em um indivìduo, para inibir fibrilogenese iapp em um indivìduo, para reduzir os agregados de amilóides associados com iapp em um indivìduo, para modular dano associado com amilóides em células, e para modular amiloidose in vivo ou ex vivo

Info

Publication number
BR0010099A
BR0010099A BR0010099-4A BR0010099A BR0010099A BR 0010099 A BR0010099 A BR 0010099A BR 0010099 A BR0010099 A BR 0010099A BR 0010099 A BR0010099 A BR 0010099A
Authority
BR
Brazil
Prior art keywords
individual
amyloids
amyloidosis
iapp
methods
Prior art date
Application number
BR0010099-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Heather Gordon
Walter Szarek
Donald Weaver
Xianqi Kong
Original Assignee
Univ Kingston
Neurochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kingston, Neurochem Inc filed Critical Univ Kingston
Publication of BR0010099A publication Critical patent/BR0010099A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
BR0010099-4A 1999-04-28 2000-04-28 Métodos para modular a agregação de amilóides em um indivìduo, para o tratamento de um estado doentio associado com amiloidose, composição para modular amiloidose, e, métodos para inibir os depósitos de amilóide associados com iapp em um indivìduo, para inibir fibrilogenese iapp em um indivìduo, para reduzir os agregados de amilóides associados com iapp em um indivìduo, para modular dano associado com amilóides em células, e para modular amiloidose in vivo ou ex vivo BR0010099A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13146499P 1999-04-28 1999-04-28
US13554599P 1999-05-24 1999-05-24
US14312399P 1999-07-09 1999-07-09
PCT/CA2000/000494 WO2000064420A2 (en) 1999-04-28 2000-04-28 Compositions and methods for treating amyloidosis using sulphonate derivatives

Publications (1)

Publication Number Publication Date
BR0010099A true BR0010099A (pt) 2002-06-04

Family

ID=27384158

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0010099-4A BR0010099A (pt) 1999-04-28 2000-04-28 Métodos para modular a agregação de amilóides em um indivìduo, para o tratamento de um estado doentio associado com amiloidose, composição para modular amiloidose, e, métodos para inibir os depósitos de amilóide associados com iapp em um indivìduo, para inibir fibrilogenese iapp em um indivìduo, para reduzir os agregados de amilóides associados com iapp em um indivìduo, para modular dano associado com amilóides em células, e para modular amiloidose in vivo ou ex vivo

Country Status (16)

Country Link
US (3) US20040198832A1 (enExample)
EP (1) EP1276483B1 (enExample)
JP (1) JP4726304B2 (enExample)
KR (2) KR20070094996A (enExample)
CN (1) CN100482233C (enExample)
AT (1) ATE441421T1 (enExample)
AU (1) AU4282400A (enExample)
BR (1) BR0010099A (enExample)
CA (1) CA2369997C (enExample)
DE (1) DE60042896D1 (enExample)
DK (1) DK1276483T3 (enExample)
ES (1) ES2331905T3 (enExample)
IL (1) IL146143A0 (enExample)
MX (1) MXPA01010835A (enExample)
NZ (1) NZ543319A (enExample)
WO (1) WO2000064420A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US6562836B1 (en) 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
EP1237547A2 (en) * 1999-07-09 2002-09-11 Isis Innovation Limited Compounds for inhibiting diseases and preparing cells for transplantation
US7311893B2 (en) 2000-07-25 2007-12-25 Neurochem (International) Limited Amyloid targeting imaging agents and uses thereof
US6716589B2 (en) * 2000-11-20 2004-04-06 Alphabeta Ab Discordant helix stabilization for prevention of amyloid formation
WO2004016261A1 (en) * 2002-08-12 2004-02-26 Yuuichi Murayama Method for suppressing proliferation of abnormal prion protein with leucine, isoleucine or valine
EA012325B1 (ru) * 2002-12-24 2009-08-28 Беллус Хелс (Интернэшнл) Лимитед Терапевтические составы для лечения болезней, связанных с наличием бета-амилоида
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
CA2529257C (en) * 2003-06-23 2013-04-23 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US7253306B2 (en) 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
NZ544686A (en) * 2003-06-23 2010-03-26 Bellus Health International Ltd Improved pharmaceutical drug candidates and methods for preparation thereof
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
EP1828111A2 (en) * 2004-11-12 2007-09-05 Neurochem (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
CN101103018A (zh) * 2004-11-16 2008-01-09 神经化学（国际）有限公司 治疗cns和淀粉样蛋白-相关疾病的化合物
JP5145537B2 (ja) * 2004-12-22 2013-02-20 ビーエイチアイ リミテッド パートナーシップ アミロイド関連疾患を治療するための方法および組成物
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
JP5607930B2 (ja) 2006-10-12 2014-10-15 ビーエイチアイ リミテッド パートナーシップ ３−アミノ−１−プロパンスルホン酸を送達するための方法、化合物、組成物および媒体
WO2008051017A1 (en) 2006-10-24 2008-05-02 Seoul National University Industry Foundation A cleavage agent selectively acting on soluble assembly of amyloidogenic peptide or protein
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
JP2011527311A (ja) * 2008-07-10 2011-10-27 ノバルティス アーゲー Ｂａｃｅ阻害薬として有用なアミノベンジル置換環状スルホン誘導体
MX380290B (es) 2015-08-10 2025-03-12 Alzheon Inc Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
WO2018156845A1 (en) 2017-02-24 2018-08-30 Alzheon, Inc. Methods for treating neurodegenerative disorders
USD852236S1 (en) 2017-08-17 2019-06-25 Samsung Electronics Co., Ltd. Refrigerator
WO2023212289A1 (en) 2022-04-28 2023-11-02 Alzheon, Inc. Tramiprosate for treating apoe4-related diseases
IL321181A (en) 2022-12-02 2025-07-01 Alzheon Inc Methods for treating neurodegenerative disorders with termiprost

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2531468A (en) * 1949-04-14 1950-11-28 Eastman Kodak Co Polyvinyl sulfonates and process for their preparation
DE1122064B (de) * 1960-01-09 1962-01-18 Basf Ag Verfahren zur Einfuehrung von alyphatischen Kohlenwasserstoffresten in organische Verbindungen, die Hydroxylgruppen, tertiaere Aminogruppen, aromatische gebundene Sulfhydrylgruppen und bzw. oder aromatisch gebundene primaere oder sekundaere Aminogruppen enthalten
US3218352A (en) * 1962-05-03 1965-11-16 Abbott Lab Homotaurine process
US3658966A (en) * 1969-09-15 1972-04-25 Kowa Co Methods of treating hypertension
US3920833A (en) * 1974-08-08 1975-11-18 Stanley Drug Products Inc Antifibrinolytic agents
FR2384751A1 (fr) * 1977-03-23 1978-10-20 Francaise Coop Pharma Nouveaux derives de la taurine a activite neuro-musculaire renforcee
CA1144937A (en) * 1977-12-22 1983-04-19 Dke J.E. Helgstrand Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
FR2457281A1 (fr) * 1979-05-23 1980-12-19 Meram Lab Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee
US4255448A (en) * 1979-09-10 1981-03-10 Wisconsin Alumni Research Foundation Method for reducing epileptiform activity
US4448779A (en) * 1981-07-16 1984-05-15 Sanofi Use of MS salt in geriatric medicine
JPS5879022A (ja) * 1981-11-04 1983-05-12 Bitamin Kenkyusho:Kk 第四級窒素原子を含有する新規な金属架橋高分子化合物、その製法及び該高分子化合物を有効成分とする高脂血症治療剤
US5087618A (en) * 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US4540564A (en) * 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
FR2529546A1 (fr) * 1982-07-05 1984-01-06 Meram Lab Nouveaux sels d'amino-(et imino-)acides a, o-sulfoniques n-substitues, vecteurs cationiques de haute penetration cellulaire
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE3229300A1 (de) * 1982-08-05 1984-02-09 Haarmann & Reimer Gmbh, 3450 Holzminden Aliphatische dicarbonsaeureester als riechstoffe und diese enthaltende parfuemkompositionen und parfuemierte produkte
US4737353A (en) * 1984-04-13 1988-04-12 Union Carbide Corporation Beryllium-aluminum-phosphorus-silicon-oxide molecular sieve compositions
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) * 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
JPH0786122B2 (ja) * 1986-05-30 1995-09-20 日本ペイント株式会社 三次元架橋された微小樹脂粒子およびその製造法
US4847082A (en) * 1987-01-21 1989-07-11 Robert Sabin Method of treatment of Alzheimer's disease using phytic acid
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
IT1205042B (it) * 1987-05-28 1989-03-10 Crinos Industria Farmaco Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5194654A (en) * 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en) * 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5164295A (en) * 1991-03-06 1992-11-17 The Upjohn Company Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
ATE147404T1 (de) * 1991-12-19 1997-01-15 Ciba Geigy Ag Aminosulfonsäurederivate und verfahren zu ihrer herstellung
US5276059A (en) * 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
US5646562A (en) * 1993-07-21 1997-07-08 Seiko Epson Corporation Phase synchronization circuit, one-shot pulse generating circuit and signal processing system
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
US5858326A (en) * 1995-06-06 1999-01-12 Neurochem, Inc. Methods of increasing amyloid deposition
DE19531342B4 (de) * 1995-08-25 2007-11-29 Merz Pharma Gmbh & Co. Kgaa Verwendung von Aminoadamantan-Verbindungen als Immunregulatoren
AU703540B2 (en) * 1996-03-26 1999-03-25 Meddiss, Incorporated Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general
CA2217322C (en) * 1996-10-03 2005-01-04 Coastside Bio Resources Inhibition of complement pathway by sea cucumber fractions
ATE491721T1 (de) * 1997-08-01 2011-01-15 Max Planck Gesellschaft Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein- aggregaten
NZ550116A (en) * 1997-08-18 2008-03-28 Neurochem Int Ltd Phosphono-carboxylate compounds for treating amyloidosis
US6294583B1 (en) * 1998-01-13 2001-09-25 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
ES2392391T3 (es) * 1998-02-11 2012-12-10 Bhi Limited Partnership Método para modular la activación de macrófagos
US6329356B1 (en) * 1998-04-10 2001-12-11 Neurochem, Inc. Phosphono-carboxylate compounds for treating amyloidosis
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
US20070135337A2 (en) * 1999-11-29 2007-06-14 Neurochem (International) Limited Vaccine for the Prevention and Treatment of Alzheimer's and Amyloid Related Diseases
US6376557B1 (en) * 2000-03-16 2002-04-23 Chanda Bhuwalka Zaveri Methods for treating alopecia
CN1774635A (zh) * 2001-03-13 2006-05-17 金斯顿皇后大学 抗癫痫发生剂
WO2003017994A1 (en) * 2001-08-31 2003-03-06 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US20040096553A1 (en) * 2002-11-20 2004-05-20 James E. Lynch Ice cream cone drip guard
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7253306B2 (en) * 2003-06-23 2007-08-07 Neurochem (International) Limited Pharmaceutical drug candidates and methods for preparation thereof
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050142191A1 (en) * 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
US20080038192A1 (en) * 2004-07-19 2008-02-14 Neurochem Inc. Diagnostic Methods Of Multiple Organ Amyloidosis
JP5145537B2 (ja) * 2004-12-22 2013-02-20 ビーエイチアイ リミテッド パートナーシップ アミロイド関連疾患を治療するための方法および組成物

Also Published As

Publication number Publication date
MXPA01010835A (es) 2003-07-14
CN100482233C (zh) 2009-04-29
WO2000064420A2 (en) 2000-11-02
IL146143A0 (en) 2002-07-25
CA2369997A1 (en) 2000-11-02
ES2331905T3 (es) 2010-01-20
KR20070094996A (ko) 2007-09-27
AU4282400A (en) 2000-11-10
KR100822525B1 (ko) 2008-04-16
CN1523992A (zh) 2004-08-25
HK1054862A1 (en) 2003-12-19
JP2003517458A (ja) 2003-05-27
EP1276483B1 (en) 2009-09-02
ATE441421T1 (de) 2009-09-15
KR20020010138A (ko) 2002-02-02
CA2369997C (en) 2009-11-17
US20090099100A1 (en) 2009-04-16
US20040198832A1 (en) 2004-10-07
EP1276483A2 (en) 2003-01-22
US20110281951A1 (en) 2011-11-17
NZ543319A (en) 2007-06-29
DK1276483T3 (da) 2009-12-14
WO2000064420A3 (en) 2002-11-07
JP4726304B2 (ja) 2011-07-20
DE60042896D1 (de) 2009-10-15

Similar Documents

Publication Publication Date Title
BR0010099A (pt) Métodos para modular a agregação de amilóides em um indivìduo, para o tratamento de um estado doentio associado com amiloidose, composição para modular amiloidose, e, métodos para inibir os depósitos de amilóide associados com iapp em um indivìduo, para inibir fibrilogenese iapp em um indivìduo, para reduzir os agregados de amilóides associados com iapp em um indivìduo, para modular dano associado com amilóides em células, e para modular amiloidose in vivo ou ex vivo
BRPI0413930A (pt) composto oligomérico ou sal farmaceuticamente aceitável deste, composição farmacêutica ou veterinária, métodos para inibir a expressão de eif4e em uma célula, tecido ou órgão, para diminuir a proliferação de uma célula em que eif4e é expressado, e para prevenir ou tratar uma condição ou doença métodos para prevenir ou diminuir a angiogênese, e o crescimento de tumor em um paciente, oligonucleotìdeo de anti-sentido, composição farmacêutica ou veterinária, e, uso de um composto oligomérico ou sal farmaceuticamente aceitável deste
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
KR890003369A (ko) 약제학적 제제
WO1997001360A3 (en) Compounds with chelation affinity and selectivity for first transition series elements and their use in medical therapy and diagnosis
KR920002144A (ko) 아연 l-카르노신 염 또는 이의 착화합물을 유효성분으로 함유하는 염증성 장질환 예방 및 치료제
NO971564L (no) 1,2-difenylpyrrolderivater, deres fremstilling og deres terapeutiske bruk
BR0312095A (pt) Composto, composição farmacêutica, e, uso de um composto
ATE207752T1 (de) Verwendung von bisphosphorsäurederivaten zur herstellung eines medikamentes zur förderung der knochenheilung
ATE202076T1 (de) Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
KR890011592A (ko) 기관내 허혈병의 치료용 조성물
BR0013065A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ ou ativação aberrante de leucócitos
AU1400801A (en) Aralkyl-1,2-diamines having calcimimetic activity and preparation mode
US4447443A (en) Anti-inflammatory/analgesic combination of α-fluoromethylhistidine and a selected non-steroidal anti-inflammatory drug (NSAID)
KR890701587A (ko) 골 손실에 관련된 질병 치료용 이미다조(1,2-a)(피리
TR200103153T2 (tr) Yeni bileşimler
KR970025615A (ko) 암 전이 억제제
SE8105561L (sv) Anvendning av pyridoxin-alfa-ketoglutarat vid profylax av hypermjolksyraemi
US5330978B1 (en) Phosphonic acid derivatives and use thereof
DE69209128D1 (de) Verwendung von Indazol-Methoxyalkansäure zur Herstellung eines Arzneimittels zur Behandlung von Autoimmunkrankheiten
HUP0104549A2 (hu) Imidazo-piridin szulfonamidszármazékok, és ezeket tartalmazó gyógyszerkészítmények
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
KR870007937A (ko) 2β-치환된 티오 메틸페니실린 유도체 및 그의 제조방법 및 용도
US4749719A (en) Method of treating skin pigmentation abnormalities with pantetheine-S-sulfonic acid
BR0011666A (pt) Derivado de pirrolpiridazina opticamente ativo ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso em derivado de pirrolpiridazina opticamente ativo, método para tratar ou prevenir doença e, processo para sintetizar um derivado de pirrolpiridazina opticamente ativo ou um sal farmaceuticamente aceitável do mesmo

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: QUEEN'S UNIVERSITY AT KINGSTON (CA), NEUROCHEM (INTERNATIONAL) LIMITED (CH)

B25G Requested change of headquarter approved

Owner name: QUEEN'S UNIVERSITY AT KINGSTON (CA) , NEUROCHEM (I

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020050084719/RJ DE 18/08/2005.

B25A Requested transfer of rights approved

Owner name: NEUROCHEM (INTERNATIONAL) LIMITED (CH)

Free format text: TRANSFERIDO DE: QUEEN'S UNIVERSITY AT KINGSTON

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 10(VIII) DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO NO 020090059307/RJ DE 16/06/2009, EM VIRTUDE DO ARQUIVAMENTO DO PEDIDO PUBLICO NA RPI 2066 DE 10/08/2010.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2138 DE 27/12/2011.

B25E Requested change of name of applicant rejected

Owner name: NEUROCHEM (INTERNATIONAL) LIMITED (CH)